Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-09T19:10:58.018Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparative Efficacy of First and Second Generation long-acting injectable antipsychotic upon schizophrenic patients: a systematic review and network metaanalysis.

Published online by Cambridge University Press:  19 July 2023

R. Medrano ,
E. Saucedo ,
C. Mancias  and
C. Saucedo
R. Medrano*
Affiliation:
Psychiatry, Departamento de Psiquiatria, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”
E. Saucedo
Affiliation:
Psychiatry, Centro de Neurociencias avanzadas, UANL, Monterrey, Mexico
C. Mancias
Affiliation:
Psychiatry, Centro de Neurociencias avanzadas, UANL, Monterrey, Mexico
C. Saucedo
Affiliation:
Psychiatry, Centro de Neurociencias avanzadas, UANL, Monterrey, Mexico
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long-acting injectable antipsychotics (LAIAs) are currently the most effective alternative for patients with schizophrenia who exhibit poor adherence. LAIAs can lead the course of treatment with the potential to increase adherence in schizophrenia treatment.

Objectives

Present the results of a network metaanalysis on the comparative efficacy of LAIs in schizophrenia.

Methods

Included trials of adults with schizophrenia compared the efficacy of LAI vs LAI or placebo through the Positive and Negative Syndrome Scale (PANSS). Efficacy was evaluated through the standarized mean differences (SMD) from baseline to endpoint in the PANSS total scores.

Results

Results from 15 studies reported usable results for PANSS score (five antipsychotics compared) are shown in Figure 1. In hierarchical order, haloperidol, aripiprazole, risperidone, and paliperidone reduced the PANSS score significantly more than other drugs.

Image:

Conclusions

Most LAIAs are equally efficient at reducing overall symptoms, and differences between individual LAIAs are non-significant.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1083
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.